Treatment with TMP195, a selective inhibitor of Class IIa HDAC, reduced critical inflammatory pathways and mitigated atherogenesis in advanced stage atherosclerosis, thereby offering a novel therapeutic strategy for reducing the consequence of vascular inflammation [129]. This evidence concerns the gene HDAC9 and atherosclerosis.